Literature DB >> 22613639

Angiotensin-converting enzyme 2 activation protects against pulmonary arterial hypertension through improving early endothelial function and mediating cytokines levels.

Gang Li1, Yu-lin Xu, Feng Ling, Ai-jun Liu, Dong Wang, Qiang Wang, Ying-long Liu.   

Abstract

BACKGROUND: Increasing evidences indicate that an activated renin-angiotensin system (RAS) causes an imbalance between the vasoconstrictive and vasodilator mechanisms involving the pulmonary circulation leading to the development of pulmonary arterial hypertension (PAH). Angiotensin-converting enzyme 2 (ACE2), a primary component of the vasoprotective axis in RAS, is recently identified that it has regulatory actions in lung pathophysiology, but the mechanism in these processes is uncertain yet.
METHODS: Severe PAH was induced by monocrotaline injection one week following pneumonectomy in rats. The activation of ACE2 by continuous injection of resorcinolnaphthalein was studied by real time-polymerase chain reaction (RT-PCR), Western blotting and fluorogenic peptide assay. Endothelial functions were evaluated by the response to acetylcholine and cytokines were measured by RT-PCR seven days after monocrotaline injection. The PAH-related hemodynamics and pathological changes were examined at day 21 when severe PAH was completely established.
RESULTS: Resorcinolnaphthalein caused significant activation of ACE2 in both normal and diseased rats in 7 days after treatment. The pulmonary arterial pressure (PAP) started to increase at least 7 days after monocrotaline injection, and the rats developed severe PAH in 21 days with high PAP, right ventricular hypertrophy and neointimal formation. Treatment with resorcinolnaphthalein prevented these features. Resorcinolnaphthalein caused an improved endothelia-dependent vasorelaxation and decrease in proinflammatory cytokines (tumor necrosis factor (TNF)-α, monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6) and increase in anti-inflammatory cytokine IL-10 in the early stage of the pathogenesis.
CONCLUSIONS: These results demonstrated that activation of ACE2 by continuous injection of resorcinolnaphthalein prevented the development of PAH through improving early endothelial dysfunction and mediating the level of proinflammatory and anti-inflammatory cytokines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22613639

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  7 in total

1.  ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats.

Authors:  Gang Li; Yinglong Liu; Yaobin Zhu; Aijun Liu; Yulin Xu; Xiaofeng Li; Zhiqiang Li; Junwu Su; Lizhong Sun
Journal:  Lung       Date:  2013-05-08       Impact factor: 2.584

2.  ACE2-angiotensin-(1-7)-Mas axis might be a promising therapeutic target for pulmonary arterial hypertension.

Authors:  Hailong Dai; Lihong Jiang; Zhicheng Xiao; Xuefeng Guang
Journal:  Nat Rev Cardiol       Date:  2015-05-05       Impact factor: 32.419

3.  Upregulation of Angiotensin (1-7)-Mediated Signaling Preserves Endothelial Function Through Reducing Oxidative Stress in Diabetes.

Authors:  Yang Zhang; Jian Liu; Jiang-Yun Luo; Xiao Yu Tian; Wai San Cheang; Jian Xu; Chi Wai Lau; Li Wang; Wing Tak Wong; Chi Ming Wong; Hui Yao Lan; Xiaoqiang Yao; Mohan K Raizada; Yu Huang
Journal:  Antioxid Redox Signal       Date:  2015-05-14       Impact factor: 8.401

Review 4.  ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy.

Authors:  Colleen T Cole-Jeffrey; Meng Liu; Michael J Katovich; Mohan K Raizada; Vinayak Shenoy
Journal:  J Cardiovasc Pharmacol       Date:  2015-12       Impact factor: 3.105

Review 5.  Inflammation: The Common Pathway of Stress-Related Diseases.

Authors:  Yun-Zi Liu; Yun-Xia Wang; Chun-Lei Jiang
Journal:  Front Hum Neurosci       Date:  2017-06-20       Impact factor: 3.169

Review 6.  It Ain't Over 'Til It's Over: SARS CoV-2 and Post-infectious Gastrointestinal Dysmotility.

Authors:  Michael J Coles; Muaaz Masood; Madeline M Crowley; Amit Hudgi; Chijioke Okereke; Jeremy Klein
Journal:  Dig Dis Sci       Date:  2022-03-30       Impact factor: 3.487

7.  The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction.

Authors:  I-Chen Chen; Jao-Yu Lin; Yi-Ching Liu; Chee-Yin Chai; Jwu-Lai Yeh; Jong-Hau Hsu; Bin-Nan Wu; Zen-Kong Dai
Journal:  Int J Med Sci       Date:  2020-09-16       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.